



# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
<b>AIMOVIG®</b> (erenumab-aooe)	Neuroscience	Pediatric Migraine	Monoclonal Antibody	3
	<b>DESCRIPTION</b> Aimovig is a monoclonal antibody that inhibits the calcitonin gene-related peptide receptor (CGRP-R). It is being investigated for prevention of chronic and episodic migraine in pediatric patients. <b>ADDITIONAL INFORMATION</b> Aimovig is developed in partnership with Novartis.			
<b>AMJEVITA™</b> (adalimumab-atto)	Inflammation	Interchangeability	Monoclonal Antibody	3
	<b>DESCRIPTION</b> AMJEVITA (adalimumab-atto) is a biosimilar to HUMIRA® (adalimumab), which is a monoclonal antibody that inhibits binding of TNF-alpha to cell surface TNF receptor / TNF-alpha. <b>ADDITIONAL INFORMATION</b> HUMIRA is a registered trademark of AbbVie Biotechnology Ltd. AMJEVITA is a trademark of Amgen Inc.			
<b>BEMARITUZUMAB</b>	Hematology/Oncology	Gastric Cancer and Gastroesophageal Junction (GEJ) Adenocarcinoma	Monoclonal Antibody	3
	<b>DESCRIPTION</b> Bemarituzumab is a monoclonal antibody that inhibits fibroblast growth factor receptor 2b (FGFR2b). It is being investigated for the treatment of advanced Gastric Cancer and Gastroesophageal Junction (GEJ) Adenocarcinoma. <b>ADDITIONAL INFORMATION</b> In April 2021, Amgen announced that the U.S. Food and Drug Administration (FDA), granted Breakthrough Therapy Designation for bemarituzumab.			
<b>BLINCYTO®</b> (blinatumomab)	Hematology/Oncology	Acute Lymphoblastic Leukemia	BiTE® Molecule	3
	<b>DESCRIPTION</b> BLINCYTO is an anti-CD19 x anti-CD3 BiTE (bispecific T cell engager) molecule. It is being investigated in newly diagnosed adults age 40 and older with Ph negative B-Cell precursor Acute Lymphoblastic Leukemia (ALL).			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
<b>EVENITY®</b> (romosozumab-aqqg)	Bone	Male Osteoporosis	Monoclonal Antibody	3
	<b>DESCRIPTION</b> EVENITY is a monoclonal antibody that inhibits the action of sclerostin. It is being investigated for the treatment of male osteoporosis.			
	<b>ADDITIONAL INFORMATION</b> EVENITY is being developed in collaboration with UCB.			
	Bone	Pediatric Osteogenesis Imperfecta	Monoclonal Antibody	1
<b>KYPROLIS®</b> (carfilzomib)	Hematology/Oncology	Multiple Myeloma	Small Molecule	3
	<b>DESCRIPTION</b> KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for weekly dosing in combinations with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma.			
	Hematology/Oncology	Pediatric Acute Lymphoblastic Leukemia	Small Molecule	2
	<b>DESCRIPTION</b> KYPROLIS is a small molecule proteasome inhibitor (PI). It is being investigated for the treatment of acute lymphoblastic leukemia (ALL) in pediatric patients.			
<b>NPLATE®</b> (romiplostim)	Hematology/Oncology	Chemotherapy-Induced Thrombocytopenia	Peptibody	3
	<b>DESCRIPTION</b> Nplate is a thrombopoietin receptor agonist (TPO-RA). It is being investigated for the treatment of chemotherapy-induced thrombocytopenia (CIT).			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
<b>OTEZLA®</b> (apremilast)	Inflammation	Pediatric Plaque Psoriasis	Small Molecule	3
	<b>DESCRIPTION</b> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe plaque psoriasis in pediatric patients.			
	Inflammation	Genital Psoriasis	Small Molecule	3
	<b>DESCRIPTION</b> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of moderate to severe genital psoriasis.			
	Inflammation	Juvenile Psoriatic Arthritis	Small Molecule	3
	<b>DESCRIPTION</b> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of juvenile psoriatic arthritis in pediatric patients.			
	Inflammation	Pediatric Behcet's Disease	Small Molecule	3
	<b>DESCRIPTION</b> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of Behcet's disease in pediatric patients.			
<b>PARSABIV®</b> (etelcalcetide)	Inflammation	Palmoplantar Pustulosis	Small Molecule	2
	<b>DESCRIPTION</b> Otezla is a small molecule that inhibits phosphodiesterase 4 (PDE4). It is being investigated for the treatment of palmoplantar pustulosis.			
<b>PARSABIV®</b> (etelcalcetide)	Nephrology	Pediatric Secondary Hyperparathyroidism	Peptide	3
	<b>DESCRIPTION</b> Parsabiv is a calcium-sensing receptor agonist. It is being investigated for the treatment of secondary hyperparathyroidism (HPT) in pediatric patients with chronic kidney disease (CKD) receiving hemodialysis.			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
<b>PROLIA®</b> (denosumab)	Bone	Pediatric Glucocorticoid-Induced Osteoporosis	Monoclonal Antibody	3
	<b>DESCRIPTION</b> Prolia is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of glucocorticoid-induced osteoporosis (GIOP) in pediatric patients.			
	Bone	Pediatric Osteogenesis Imperfecta	Monoclonal Antibody	3
	<b>DESCRIPTION</b> Prolia is a monoclonal antibody that inhibits RANK ligand. It is being investigated for the treatment of osteogenesis imperfecta in pediatric patients.			
<b>REPATHA®</b> (evolocumab)	Cardiometabolic	Hypercholesterolemia	Monoclonal Antibody	3
	<b>DESCRIPTION</b> Repatha is a monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). It is being investigated for the treatment of patients with high-risk cardiovascular disease without prior heart attack or stroke.			
<b>TEZSPIRE™</b> (tezepelumab-ekko)	Inflammation	Severe Asthma	Monoclonal Antibody	3
	<b>DESCRIPTION</b> Tezspire is a monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of severe asthma.			
	<b>ADDITIONAL INFORMATION</b> Following a priority review by the U.S. FDA, Tezspire was approved in December 2021 for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Regulatory reviews are underway in the EU, Japan, and other jurisdictions.			
	Tezspire is being developed in collaboration with AstraZeneca plc.			
	INFLAMMATION	Severe Asthma	Monoclonal Antibody	3
	<b>DESCRIPTION</b> Tezepire is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP).			
	<b>ADDITIONAL INFORMATION</b> Tezspire is being developed in collaboration with AstraZeneca plc.			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
<b>TEZSPIRE™</b> (tezepelumab-ekko)	Inflammation	Chronic Obstructive Pulmonary Disease	Monoclonal Antibody	2
	<b>DESCRIPTION</b> Tezepire is a monoclonal antibody that inhibits the action of the thymic stromal lymphopoietin (TSLP). It is being investigated for the treatment of chronic obstructive pulmonary disease (COPD).			
	<b>ADDITIONAL INFORMATION</b> Tezepire is being developed in collaboration with AstraZeneca plc.			
	Inflammation	Chronic Spontaneous Urticaria	Monoclonal Antibody	2
<b>ABP 654</b> (Investigational biosimilar to STELARA® (ustekinumab))				
	Inflammation	Investigational Biosimilar	Monoclonal Antibody	3
	<b>DESCRIPTION</b> ABP 654 is an investigational biosimilar to STELARA (ustekinumab), which is a monoclonal antibody that inhibits IL-12 and IL-23.			
	<b>ADDITIONAL INFORMATION</b> STELARA is a registered trademark of Johnson & Johnson.			
<b>ABP 938</b> (Investigational biosimilar to EYLEA® (afibercept))				
	Inflammation	Investigational Biosimilar	Fusion Protein	3
	<b>DESCRIPTION</b> ABP 938 is an investigational biosimilar to EYLEA (afibercept), which is a vascular endothelial growth factor receptor (VEGFR) Fc fusion protein.			
	<b>ADDITIONAL INFORMATION</b> EYLEA is a registered trademark of Regeneron Pharmaceuticals, Inc.			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.





# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
ABP 959 (Investigational biosimilar to SOLIRIS® (eculizumab))	Hematology/Oncology	Investigational Biosimilar	Monoclonal Antibody	3
	<p><b>DESCRIPTION</b></p> <p>ABP 959 is an investigational biosimilar to SOLIRIS (eculizumab), which is a monoclonal antibody that specifically binds to the complement protein C5.</p> <p><b>ADDITIONAL INFORMATION</b></p> <p>SOLIRIS is a registered trademark of Alexion Pharmaceuticals Inc.</p>			
EFAVALEUKIN ALFA (formerly AMG 592)	Inflammation	Systemic Lupus Erythematosus	Fusion Protein	2
	<p><b>DESCRIPTION</b></p> <p>Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of systemic lupus erythematosus.</p>			
	Inflammation	Ulcerative Colitis	Fusion Protein	2
	<p><b>DESCRIPTION</b></p> <p>Efavaleukin alfa (formerly AMG 592) is an IL-2 mutein Fc fusion protein. It is being investigated for the treatment of ulcerative colitis.</p>			
OLPASIRAN (formerly AMG 890)	Cardiometabolic	Cardiovascular Disease	siRNA	2
	<p><b>DESCRIPTION</b></p> <p>Olpasiran (formerly AMG 890) is a small interfering RNA (siRNA) that lowers lipoprotein(a), also known as Lp(a). It is being investigated for the treatment of atherosclerotic cardiovascular disease.</p>			
LUMAKRAS® (sotorasib)	Hematology/Oncology	Non-Small Cell Lung Cancer	Small Molecule	2
	<p><b>DESCRIPTION</b></p> <p>LUMAKRAS is a KRAS<sup>G12C</sup> small molecule inhibitor under investigation for the treatment of advanced non-small cell lung cancer.</p> <p><b>ADDITIONAL INFORMATION</b></p> <p>LUMAKRAS received accelerated approval by the FDA in May 2021 for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, following at least one prior systemic therapy. Marketing authorization has subsequently been granted in the European Union as well as in additional countries, including some under FDA's Project Orbis initiative, such as Canada and U.K. Additional marketing applications are also under review.</p> <p><b>ADDITIONAL CLINICAL STUDIES</b></p> <p>LUMAKRAS is also in Phase 1 and Phase 2 development for the treatment of NSCLC as monotherapy and in combination with other therapies.</p>			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
<b>LUMAKRAS®</b> (sotorasib)	Hematology/Oncology	Advanced Colorectal Cancer	Small Molecule	2
	<b>DESCRIPTION</b> LUMAKRAS is a KRAS <sup>G12C</sup> small molecule inhibitor under investigation for the treatment of advanced colorectal cancer.			
	<b>ADDITIONAL INFORMATION</b> LUMAKRAS is being investigated in previously treated KRAS G12C-mutated CRC as monotherapy and in combination with other therapies.			
	Hematology/Oncology	Other Tumors	Small Molecule	2
	<b>DESCRIPTION</b> LUMAKRAS is a KRAS <sup>G12C</sup> small molecule inhibitor under investigation for the treatment of advanced solid tumors other than non-small cell lung cancer or advanced colorectal cancer.			
	<b>ADDITIONAL INFORMATION</b> LUMAKRAS is being investigated in previously treated KRAS G12C-mutated solid tumors as monotherapy and in combination with other therapies.			
<b>ROZIBAFUSP ALFA</b> (formerly AMG 570)	Inflammation	Systemic Lupus Erythematosus	Antibody-Peptide Conjugate	2
	<b>DESCRIPTION</b> Rozibafusp alfa (formerly AMG 570) is a novel antibody-peptide conjugate that simultaneously blocks ICOSL and BAFF activity. It is being investigated for the treatment of systemic lupus erythematosus.			
<b>ORDESEKIMAB</b> (formally AMG 714 / PRV)	Inflammation	Celiac Disease	Monoclonal Antibody	2
	<b>DESCRIPTION</b> Ordesekimab (formally AMG 714) is a monoclonal antibody that inhibits the action of Interleukin-15 (IL-15). It is being investigated for the treatment of celiac disease.			
	<b>ADDITIONAL INFORMATION</b> Ordesekimab is being developed in collaboration with Provention Bio.			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
<b>TARLATAMAB</b> (formerly AMG 757)	Hematology/Oncology	Small Cell Lung Cancer	BiTE® Molecule	2
	<b>DESCRIPTION</b> Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of small cell lung cancer.			
	Hematology/Oncology	Neuroendocrine Prostate Cancer	BiTE® Molecule	1
	<b>DESCRIPTION</b> Tarlatamab (formerly AMG 757) is a half-life extended (HLE) anti- delta-like ligand 3 (DLL3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of neuroendocrine prostate cancer.			
<b>AMG 451 / KHK4083</b>	Inflammation	Atopic Dermatitis	Monoclonal Antibody	2
	<b>DESCRIPTION</b> AMG 451 (KHK4083) is a monoclonal antibody that inhibits OX-40. It is being investigated for the treatment of moderate-to-severe atopic dermatitis.			
	<b>ADDITIONAL INFORMATION</b> AMG 451 (KHK4083) is being developed in collaboration with Kyowa Kirin Co., Ltd.			
<b>ACAPATAMAB</b> (formerly AMG 160)	Hematology/Oncology	Prostate Cancer	BiTE® Molecule	1
	<b>DESCRIPTION</b> Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of prostate cancer.			
	Hematology/Oncology	Non-Small Cell Lung Cancer	BiTE® Molecule	1
	<b>DESCRIPTION</b> Acapatamab (formerly AMG 160) is a half-life extended (HLE) anti- prostate-specific membrane antigen (PSMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of non-small cell lung cancer (NSCLC).			
<b>PAVURUTAMAB</b> (formerly AMG 701)	Hematology/Oncology	Multiple Myeloma	BiTE® Molecule	1
	<b>DESCRIPTION</b> Pavurutamab (formerly AMG 701) is a half-life extended (HLE) anti-B-cell maturation antigen (BCMA) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of multiple myeloma.			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.





# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 104	Inflammation	Asthma	Monoclonal Antibody	1
	<b>DESCRIPTION</b> AMG 104 is a human anti-TSLP Fab. It is being investigate for the treatment of asthma.			
	<b>ADDITIONAL INFORMATION</b> AMG 104 is being developed in collaboration with AstraZeneca plc.			
AMG 119	Hematology/Oncology	Small Cell Lung Cancer	CAR-T	1
	<b>DESCRIPTION</b> AMG 119 is a delta-like ligand 3 (DLL3) chimeric antigen receptor T cell (CAR T) cellular therapy. It is being investigated for the treatment of small cell lung cancer.			
AMG 133	Cardiometabolic	Obesity	Antibody-Peptide Conjugate	1
	<b>DESCRIPTION</b> AMG 133 is a gastric inhibitory polypeptide receptor (GIPR) antagonist and glucagon-like peptide 1 (GLP-1) receptor agonist. It is being investigated for the treatment of obesity.			
AMG 176	Hematology/Oncology	Hematology	Small Molecule	1
	<b>DESCRIPTION</b> AMG 176 is a small molecule inhibitor of myeloid cell leukemia 1 (MCL-1). It is being investigated for the treatment of hematologic malignancies.			
AMG 193	Hematology/Oncology	Solid Tumors	Small Molecule	1
	<b>DESCRIPTION</b> AMG 193 is a small molecule methylthioadenosine (MTA) cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor.. It is being investigated for the treatment of solid tumors.			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 199	Hematology/Oncology	Solid Tumors	BiTE® Molecule	1
	<b>DESCRIPTION</b> AMG 199 is a half-life extended (HLE) anti-MUC17 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of MUC17-Positive Solid Tumors including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers.			
AMG 256	Hematology/Oncology	Solid Tumors	Bifunctional Fusion Protein	1
	<b>DESCRIPTION</b> AMG 256 (anti-PD-1 x IL21 mutein) is a targeted IL-21 receptor agonist designed to selectively turn on the Interleukin 21 (IL-21) pathway in programmed cell death-1 (PD-1) positive cells. It is being investigated for the treatment of solid tumors.			
AMG 330	Hematology/Oncology	Acute Myeloid Leukemia	BiTE® Molecule	1
	<b>DESCRIPTION</b> AMG 330 is an anti-CD33 x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of acute myeloid leukemia.			
AMG 340	Hematology/Oncology	Prostate Cancer	Bispecific T-Cell Engager	1
	<b>DESCRIPTION</b> AMG 340 (previously TNB 585) is an anti-prostate-specific membrane antigen (PSMA) x anti-CD3 Bispecific T cell engager and is designed using the human heavy chain antibody platform. It is being investigated for the treatment of prostate cancer.			
AMG 404	Hematology/Oncology	Solid Tumors	Monoclonal Antibody	1
	<b>DESCRIPTION</b> AMG 404 is an anti-programmed cell death-1 (PD-1) monoclonal antibody being investigated as a treatment for patients with solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules.			
AMG 427	Hematology/Oncology	Acute Myeloid Leukemia	BiTE® Molecule	1
	<b>DESCRIPTION</b> AMG 427 is a half-life extended (HLE) anti-fms-like tyrosine kinase 3 (FLT3) x anti-CD3 bispecific T cell engager (BiTE) molecule. It is being investigated for the treatment of acute myeloid leukemia (AML).			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.



# PIPELINE

A robust pipeline leveraging state-of-the-art science and molecular engineering focused on the pursuit of transformative medicines with large effects in serious diseases. Human genetic validation is used to strengthen the evidence base of as many of our programs as possible.

MOLECULE NAME	THERAPEUTIC AREA	INVESTIGATIONAL INDICATION	MODALITY	PHASE
AMG 506	Hematology/Oncology	Solid Tumors	DARPin® protein	1
	<b>DESCRIPTION</b> AMG 506 is a multi-specific FAP x 4-1BB-targeting DARPin biologic under investigation as a treatment for solid tumors. It is being developed for use in combination with other Amgen oncology portfolio molecules.			
	<b>ADDITIONAL INFORMATION</b> AMG 506 (also known as MP0310) is being developed in collaboration with Molecular Partners AG. DARPin is a registered trademark owned by Molecular Partners AG.			
AMG 509	Hematology/Oncology	Prostate Cancer	XmAb® Antibody	1
	<b>DESCRIPTION</b> AMG 509 (STEAP1 XmAb antibody) is a bivalent T cell engager and is designed using XmAb 2+1 technology. It is being investigated for the treatment of prostate cancer.			
	<b>ADDITIONAL INFORMATION</b> XmAb is a registered trademark of Xencor, Inc.			
AMG 609	Metabolic Disorders	Nonalcoholic Steatohepatitis	siRNA Small Molecule	1
	<b>DESCRIPTION</b> AMG 609 is a small interfering RNA (siRNA) that selectively targets a variant allele of patatin like phospholipase domain containing 3, also known as PNPLA3 I148M. It is being investigated for the treatment of nonalcoholic steatohepatitis (NASH).			
AMG 650	Hematology/Oncology	Solid Tumors	Small Molecule	1
	<b>DESCRIPTION</b> AMG 650 is a small molecule KIF18A inhibitor. It is being investigated as a treatment for advanced solid tumors.			
AMG 994	Hematology/Oncology	Solid Tumors	Bifunctional Fusion Protein	1
	<b>DESCRIPTION</b> AMG 994 is a bispecific antibody. It is being investigated for the treatment of non-small cell lung cancer, mesothelioma, pancreatic cancer and ovarian cancer.			

\*Modalities in use across pipeline and marketed products. Modality refers to the structural template of a therapeutic agent.

This pipeline presents a selection of the Company's product candidates and is designed to demonstrate the range of the Company's commitment to patients in pursuing therapies to treat serious illnesses. We present a selection of these product candidates in our periodic reports based on their importance to the Company and our Annual Report on Form 10-K also includes an annual summary of activity for those Phase 3 product candidates selected for inclusion in our periodic filings. Unless otherwise noted, we are providing this information as of February 8, 2022 and expressly disclaim any duty to update any of the provided information. Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing through clinical phases to licensure and market, returning to strategic partners, being outlicensed, or failing in clinical trials to demonstrate efficacy, safety or to deliver a commercially viable product, due to the nature of the development process. This description contains forward-looking statements that involve significant risks and uncertainties, including those discussed in Amgen's most recent Form 10-K and in Amgen's periodic reports on Form 10-Q and Form 8-K, and actual results may vary materially. Amgen is providing this information as of the date above and does not undertake any obligation to update any forward-looking statements contained in this table as a result of new information, future events or otherwise.